AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03255928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PAS assay, TGT
Description: Evaluation of platelet function
Study NCT02712918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression
Description: Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
Study NCT02712918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Treatment as usual at the ward
Study NCT03565705 — intervention group
Intervention type: PROCEDURE
Intervention: Open abdominal prostatectomy
Description: Patients undergo standardized open abdominal prostatectomy.
Study NCT03304106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercially available cochlear implant and AI system
Description: Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
Study NCT03195322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-pectoral Tissue Expander
Description: All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
Study NCT02511132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.
Study NCT02511132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
Study NCT02511132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
Study NCT02511132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
Study NCT02511132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV administered on Day 8 and every 21 days
Study NCT02888990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT02665741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus transparent cap
Description: distal colonoscope attachment
Study NCT02665741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medivators Endocuff
Description: distal colonoscope attachment
Study NCT02665741 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: No distal colonoscope attachments
Study NCT02121548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW Outreach and HPV Self-sampling
Description: The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
Study NCT02121548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW Outreach
Description: The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
Study NCT02121548 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CHW Outreach
Description: The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
Study NCT02307149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAVATAK
Description: CAVATAK is a preparation of CVA21
Study NCT02307149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
Study NCT03112226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GnRHant + E2
Description: GnRH antagonist with estradiol add-back
Study NCT03112226 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GnRHant + Placebo
Description: GnRH antagonist with placebo add-back
Study NCT02217852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Description: doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
Study NCT02217852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
Study NCT02217852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril,Hydrochlorothiazide
Description: doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
Study NCT02217852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beijing hypotensive No.0
Description: 1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
Study NCT03094793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abnormal EEGs
Description: This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention.
Study NCT03130933 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lower third molar surgery
Description: All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures.
Study NCT03130933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower third molar surgery
Description: All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures.
Study NCT03130933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
Study NCT03130933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
Study NCT01983826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate
Description: Sodium Nitrate (1g/day) for 8 weeks
Study NCT01983826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose (daily) for 8 weeks
Study NCT02841384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: taping patellar McConnell
Description: Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
Study NCT02841384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo taping
Description: Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
Study NCT06038500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention of resistance exercises, dancing sessions and nutritional education
Description: The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
Study NCT00616876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
Study NCT00616876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
Study NCT02696486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
Study NCT03230435 — intervention group
Intervention type: OTHER
Intervention: Treatment settings as usual.
Description: Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
Study NCT03457818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
Study NCT03457818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
Study NCT01393522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
Study NCT01393522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
Study NCT01696656 — intervention group
Intervention type: DRUG
Intervention: Drug prescription pattern
Description: Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
Study NCT02229799 — intervention group
Intervention type: DRUG
Intervention: Actilyse
Study NCT01955239 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated Radiotherapy
Study NCT01955239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated Radiotherapy
Study NCT02313623 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate Fusion Biopsy
Description: For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
Study NCT00730574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 + Folic Acid
Description: Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
Study NCT00116714 — intervention group
Intervention type: DRUG
Intervention: DMARD
Description: All subjects were required to initiate, add or change DMARD therapy at study entry.
Study NCT03793192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PACE2 Intervention
Description: Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
Study NCT01229969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Fit Balance Games
Description: Ski Slaloms and Table Tilt
Study NCT01229969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroCom EquiTest® System
Description: Sensory Organization Test (SOT) and Limit of Stability (LOS).
Study NCT01721447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison echocardiography contrast agent
Description: Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
Study NCT03782987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: 0 mg BI 730357 tablet orally on Day 1
Study NCT03782987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
Study NCT00826566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 2 times 250 mg caffeine per day
Study NCT00826566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 times 250 mg per day
Study NCT02781818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 10mg/mL
Description: Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
Study NCT02781818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
Study NCT02781818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline 0.1 mL will be administered intralesionally at the selected site.
Study NCT02168023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DACC impregnated dressing
Description: DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
Study NCT02168023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical dressing
Description: Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
Study NCT00905567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 2 x 25 mg tablet
Study NCT00905567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Tablet 2 x 25 mg
Study NCT03046771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transport PLUS group
Description: The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
Study NCT04478318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uEXPLORER/mCT
Description: Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.
Study NCT04478318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mCT/uEXPLORER
Description: Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner
Study NCT04544046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Description: Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
Study NCT04544046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care arm will receive standard oncology care and attend regular clinic visits.
Study NCT02861781 — intervention group
Intervention type: OTHER
Intervention: Collection of blood samples and tissues
Description: Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
Study NCT02019550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebif Rebidose
Description: Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
Study NCT02019550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebiject II
Description: Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
Study NCT03365934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHESIVE BANDAGE #1
Description: Bandage applied daily to wounded site for 14 days
Study NCT03365934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHESIVE BANDAGE #2
Description: Bandage applied daily to wounded site for 14 days
Study NCT03365934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHESIVE BANDAGE #3
Description: Bandage applied daily to wounded site for 14 days
Study NCT03365934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antibacterial Bandage with 0.8% BZK
Description: bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
Study NCT03365934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intact and No Bandage
Description: This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
Study NCT03365934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wounded and No Bandage
Description: This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
Study NCT02537600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib + Vemurafenib combination treatment
Description: Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.